Parallel Advisors LLC Purchases Shares of 220,000 CERo Therapeutics Holdings, Inc. (NASDAQ:CERO)

Parallel Advisors LLC purchased a new stake in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the first quarter, HoldingsChannel.com reports. The firm purchased 220,000 shares of the company’s stock, valued at approximately $161,000. Parallel Advisors LLC owned approximately 0.07% of CERo Therapeutics at the end of the most recent reporting period.

Separately, Avantax Planning Partners Inc. increased its stake in shares of CERo Therapeutics by 89.9% in the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after buying an additional 1,224,021 shares in the last quarter. 29.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CERO shares. D. Boral Capital restated a “hold” rating on shares of CERo Therapeutics in a research note on Friday, May 30th. D Boral Capital lowered CERo Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 30th. Finally, Maxim Group began coverage on CERo Therapeutics in a research note on Monday, May 19th. They issued a “buy” rating and a $3.00 target price for the company.

CERo Therapeutics Price Performance

Shares of NASDAQ:CERO opened at $0.43 on Friday. CERo Therapeutics Holdings, Inc. has a 1-year low of $0.40 and a 1-year high of $102.00. The business has a 50-day moving average price of $0.67 and a two-hundred day moving average price of $3.78.

CERo Therapeutics (NASDAQ:CERO) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($1.59) earnings per share for the quarter.

CERo Therapeutics Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.